This study examines the role of endothelial leukocyte adhesion molecule-i in the development of the acute airway inflammation (cell influx) and late-phase airway obstruction in a primate model of extrinsic asthma. In animals sensitive to antigen, a single inhalation exposure induced the rapid expression of ELAM-1 (6 h) exclusively on vascular endothelium that correlated with the influx of neutrophils into the lungs and the onset of late-phase airway obstruction. In contrast, basal levels of ICAM-1 was constitutively expressed on vascular endothelium and airway epithelium before antigen challenge. After the single antigen exposure, changes in ICAM-1 expression did not correlate with neutrophil influx or the change in airway caliber. This was confirmed by showing that pretreatment with a monoclonal antibody to ICAM-1 did not inhibit the acute influx of neutrophils associated with late-phase airway obstruction, whereas a monoclonal antibody to ELAM-1 blocked both the influx of neutrophils and the late-phase airway obstruction. This study demonstrates a functional role for ELAM-1 in the development of acute airway inflammation in vivo. We conclude that, in primates, the late-phase response is the result of an ELAM-1 dependent influx of neutrophils. Therefore, the regulation of ELAM-1 expression may provide a novel approach to controlling the acute inflammatory response, and thereby, affecting airway function associated with inflammatory disorders, including asthma. (J. Clin. Invest.
Introduction
It is well documented that inhalation ofallergens by susceptible asthmatics causes the occurrence of an immediate airway obstruction that is maximal at 10-20 min and resolves by 1-2 h post-antigen exposure. Many also experience a second, late asthmatic response characterized by prolonged bronchial ob-struction, the onset of which usually begins 4-5 h after initial allergen exposure and may persist for up to 24 h or more (1, 2) .
The development of airway inflammation and the role of proinflammatory cells in the clinical manifestations of asthma have become the subject of profound investigation. In particular, many recent studies have suggested an active role for nonresident proinflammatory cells that actively infiltrate the lung and selectively release on specific target tissue, potent preformed and/or newly generated proinflammatory mediators that contribute to the late-phase response (3, 4) .
The accumulation of polymorphonuclear leukocytes at sites of inflammation is dependent upon a complex series of events. Of particular interest is the upregulation and enhanced expression of cell surface adhesion glycoproteins on vascular endothelium and circulating leukocytes leading to leukocyte adherence to the vessel wall, activation, and subsequent extravasation. In the present study we have examined the function oftwo vascular adhesion molecules, intercellular adhesion molecule-l (ICAM-l)' and endothelial leukocyte adhesion molecule-I (ELAM-1), in the development ofantigen-induced acute airway inflammation and the associated late-phase airway obstruction in primates.
Methods
Animals. The animals used in this study were Study protocol. Each animal was anesthetized with an intramuscular injection ofketamine (4 mg/kg; Ketaset; Myoderm Medical Supply, Norristown, PA) and xylazine (I mg/kg; Rompun; Miles Laboratories, Inc., Naperville, IL), intubated with a cuffed endotracheal tube, and placed in the supine position. Ketamine (4 mg/kg, i.m.) was used as supplemental anesthesia as needed. Each animal then received a bolus intravenous injection of monoclonal antibody or vehicle (saline). Airway and tissue cellular composition was then evaluated by performing bronchoalveolar lavage (BAL) with a pediatric fiberoptic bronchoscope and bronchial biopsy, after which the animals were seated in the upright position in a specially designed support chair. Baseline respiratory system resistance (Rrs) was monitored for -15 min followed by an inhaled antigen challenge (I h post-iv treatment). Rrs was monitored continuously for I h after which the animals were allowed to recover from anesthesia and returned to their cages. At 4, 6, 8 , and 10 h after antigen inhalation the animals were anesthetized (ketamine/xylazine), intubated, and Rrs was monitored over a 15-min time period to record the late-phase response. Cellular influx into the lungs during the peak late-phase response was assessed by performing BAL (opposite lung lavaged before antigen challenge) and bronchial biopsy.
The study was designed such that bracketing control experiments (vehicle treatment) were performed on each animal such that each animal represents its own control. Each study was separated by 14 d.
MAbs. An anti-human ELAM-I MAb was prepared by immunizing BALB/c mice with human umbilical vein endothelial cells (HU-VEC) isolated and cultured as previously described (5), and stimulated with IL-l (3 U/ml) for 4 h. The immunization schedule and preparation of hybridomas was performed as previously described (6) , and clone selection was based on the detection ofnewly expressed endothelial antigens after 4 h stimulation of HUVEC with 3 U/ml IL-1. One MAb selected for the present study, CL2, was found to recognize selectively COS cells and L cells transfected with ELAM-I cDNA but not LFA-3 or ICAM-I cDNA (Kishimoto, T. K., R. A. Warnock, M. A. Jutila, E. C. Butcher, C. L. Lane, D. C. Anderson, and C. W. Smith, submitted for publication). This MAb also immunoprecipitated a 1 5-kD surface glycoprotein from IL-l-stimulated HUVEC, and in adhesion studies in vitro, significantly inhibited the adhesion ofCDl 8-deficient human neutrophils to IL-I -stimulated HUVEC. The binding pattern of CL2 was tested with monkey leukocytes and found to weakly bind to neutrophils and lymphocytes. However, this antibody does not inhibit neutrophil or lymphocyte function (i.e., aggregation, chemotaxis). In addition, intravenous treatment with the MAbs does not alter the circulating white cell count as previously described (7).
Antibodies against ICAM-l were generated as previously described (7). Stock MAb solutions were diluted with saline (concentration, 2 mg/ml) immediately before intravenous injection into a peripheral leg vein. MAb treatment was administered I h before antigen inhalation challenge. This timing was based on previous work (7) where we showed functional activity with these monoclonol antibodies. Rrs measurements. Respiratory system impedance (Zrs) was measured by discrete frequency (4- Histochemistry. The typing ofBAL cells were evaluated using cytocentrifuge preparations stained with Diff-Quick stain (Fisher Scientific Co., St. Louis, MO). Differential cell counts were determined by counting 200 cells and the percentages of each cell type was recorded.
Histology. Lung biopsy samples were obtained before antigen challenge and during the peak late-phase response with biopsy forceps and the fiberoptic bronchoscope. Immunohistochemical staining for identification of ICAM-I and ELAM-I on pulmonary vascular endothelium and airway epithelium was performed as previously described (7).
Statistical analysis. Data were analyzed statistically using a twoway analysis of variance and Friedman's multiple range test.
Results
In the first series of experiments we examined the lung cellular composition, by BAL, before and at several time points after a single antigen challenge (Fig. 1) . Before antigen challenge there were a large number of eosinophils recovered by BAL. At 6 h postchallenge (during the peak late-phase airway obstruction) the number of eosinophils decreased but returned to prechallenge values by day 1. Eosinophils remained chronically elevated at days 7 and 14. Neutrophils, however, comprised a very small percentage of BAL cells before antigen challenge and were dramatically increased at the peak of the late-phase airway obstruction (6 h). Neutrophils returned to basal levels by day 1 and remained low at days 7 and 14. The influx of neutrophils correlated significantly with the magnitude of the latephase response (r = 0.61; P < 0.05).
Immunohistochemical staining oflung tissue revealed positive staining for ICAM-I on both pulmonary vascular endothelium and airway epithelium 6 h after inhalation challenge (Fig.  2) . In contrast, staining for ELAM-l was clearly increased only on pulmonary vascular endothelium 6 h postchallenge. No staining for ELAM-l was found on airway epithelium.
Pretreatment with the anti-ELAM-l monoclonal antibody (CL2) 1 h before antigen inhalation significantly attenuated both the total leukocyte infiltration and the number ofinfiltrating neutrophils in all animals, markedly in three animals (Fig.  3) . Pretreatment with the anti-ICAM-l monoclonal antibody (R6.5) did not significantly alter the number ofinfiltrating leu- kocytes recovered by BAL or the neutrophil influx (Fig. 4) . CL2 treatment resulted in a significant reduction in the latephase response, whereas R6.5 had no effect (Fig. 5) . Neither treatment had an effect on the early response.
Discussion
Adhesion molecules are critical in the extravasation of neutrophils to sites ofinflammation. The need for the CD1 8 integrins is clearly shown by the fact that neutrophil infiltration in infected lesions is almost absent in patients with CD18 deficiency (9) . The use of anti-CD 1 8 and anti-ICAM-l MAbs in various animal models has also demonstrated that CD1 8 integrins and ICAM-l are needed for neutrophil emigration at many inflammatory sites (10) (11) (12) . In addition though, recent evidence indicates that CD I 8-independent mechanisms are required foremigration of neutrophils in some inflammatory conditions in the lungs ofrabbits and humans (10, 13) . Studies in vitro show that CDl 8-independent neutrophil-endothelial adhesion involves members ofthe LEC-CAM family of adhesion molecules (14) (15) (16) (17) (18) (19) (27) . These studies have shown Interestingly, treatment with anti-ICAM-l did not block the neutrophil influx and late-phase response. We conclude from this that ICAM-I is not the predominant adhesion protein involved in the acute airway inflammatory response. Of note is that we have shown previously that ICAM-1 does play a pivital role in the development ofchronic airway inflammation and the associated airway hyperresponsiveness induced with multiple inhalation antigen challenges (7) . In these studies R6.5 (anti-ICAM-1) significantly reduced the airway eosinophilia and prevented any increase in airway responsiveness to inhaled methacholine. In contrast to the role ofthe eosinophil in the chronically inflamed lung, we see little change in the number of neutrophils. In another recent study of chronic airway inflammation (28) , we demonstrated that neutrophil influx only occurs during the recovery phase when airway function and hyperresponsiveness are returning to preinflammatory values and, therefore, suggest that the neutrophil has a predominantly reparative role in chronic airway inflammation. Thus, together the data presented suggests a functional role for both ELAM-l and ICAM-l in antigen-induced acute and chronic airway inflammation, respectively. Furthermore, data from this study and from previous studies from our laboratory demonstrate important differences in the role of cellular adhesion molecules and proinflammatory cell types in acute or chronic airway inflammation. 
